Earth Science Tech Strengthens Advisory Board with

Hollywood, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"),   an innovative biotech company, which focuses on cannabis-industrial hemp, cannabinoid research and development, nutraceuticals and pharmaceuticals is proud to announce that four new scientists and doctors have joined the company’s Advisory Board. ETST strategy of recruiting industry experts to help expand and increase the Development of Cannabinoids' Therapeutic Indications, R&D, Technology, IP and Treatments. These Four Distinguished Scientists and Doctors will serve on the board of advisory for Earth Science Tech and or its two (2) wholly owned subsidiaries, Cannabis Therapeutics Inc., and Earth Science Pharmaceutical Inc.

Dr. Laurent Azoulay, PhD. Laurent Azoulay, Ph.D., has joined both the Cannabis Therapeutics Inc. and Earth Science Pharmaceutical Inc. Advisory Boards. He is an Associate Professor of Oncology at McGill University, where he actively researches cancer pharmacoepidemiology, which includes evaluating the safety of cancer drugs at a societal level.

After receiving his PhD in 2007 from the Université de Montréal, he completed a postdoctoral fellowship in pharmacoepidemiology at the Department of Epidemiology, Biostatistics and Occupational Health, McGill University. He then joined the Gerald Department of Oncology as an Assistant Professor in 2009. In 2016, he was promoted to the rank of Associate Professor with a cross-appointment with the Department of Epidemiology, Biostatistics and Occupational Health.

Dr. Chandra Panchal, PhD. Chandra Panchal, Ph.D., has joined the Cannabis Therapeutics Inc., Earth Science Pharmaceutical Inc., and Earth Science Tech Inc. Advisory Boards. He is a serial entrepreneur with a wealth of expertise acquired from 28 years of experience in the biotech/pharmaceutical sector.

Dr. Panchal founded Axcelon in 2001 and was a co-founder of Procyon Biopharma Inc., a publicly traded biotechnology company involved in the development of wound healing, cancer therapeutic, and diagnostic products. Now known as Ambrilia BioPharma Inc., the company listed on the Alberta Stock Exchange in 1998 and the TSX in 2000. He served as Procyon Biopharma Inc.’s Chairman, President, and CEO; and Ambrilia Biopharma Inc.’s Senior Executive Vice-President, Business Development, Licensing, and Intellectual Property in charge of both out-licensing, in-licensing and M&A activities. He retired from Ambrilia Biopharma Inc. in February 2008.

Since then, Dr. Panchal has been actively involved in Axcelon.  Prior to founding Procyon Biopharma Inc., Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentations, and product development at John Labatt Ltd., a multinational food and beverage company. Dr. Panchal sits on the board of directors of several public and private companies.  He has authored/co-authored over 60 scientific papers and has edited a book entitled Yeast Strain Selection. Dr. Panchal has been an Adjunct Professor at the University of Western Ontario where he obtained his Ph.D. in biochemical engineering.

Dr. Domenico Fuoco, PhD. Domenico Fuoco, Ph.D., has joined the Cannabis Therapeutics Inc. Advisory Board. Dr. Fuoco has over 16 years’ experience in the research and development of innovative solutions for the pharmaceutical industry. Dr. Fuoco trained at the prestigious Department of Oncology of McGill University Health Centre (MUHC) in Montreal, from 2012 to 2015. During this time, Dr. Fuoco worked on the next generation of medications for AVEO Oncology and Helsinn Therapeutics.  Prior to this, Dr. Fuoco obtained his PhD and Post-Doc training in medicinal chemistry and drug discovery at the University of Perugia in Italy with further studies at the University of Salamanca School of Pharmacy in Spain.

Dr. Fuoco is recognized for the transdisciplinary approach of his work. In 2010, Dr. Fuoco was Principal Scientist of the Italian Mission in Amazonia, Bogotà, Colombia.  Dr. Fuoco’s publications cover a wide-range of chemical fields, from functional foods to autoimmune diseases. In 2015, Dr. Fuoco was honored with the prestigious Dr. Henry Shibata Fellowship from the Cedar Cancer Foundation for his work in the field of palliative care. Dr. Fuoco is an active member of the Italian Canadian Community Foundation and is very active within his community.  He is also the chairman from Smart Medicines Consortium for the advancement of health care.

Dr. Fuoco’s expertise in human health and functional foods are highly valued as strategic assets by ETST.

Calvin Higgins, M.D. Calvin Higgins, M.D., has joined the Earth Science Tech Inc. Advisory Board. Dr. Calvin Higgins is board-certified in internal medicine. Diplomate of the American Board of Internal Medicine. He was born in Kingston, Jamaica. He came to the United States in 1979. He attended Cornell Medical School and graduated in 1985. In 1998, he completed his residency at Lenox Hill Medical Center in Manhattan, New York in Internal Medicine. In 1998 he moved to Florida and completed 3 years in office-based medicine. He then moved onto hospital-based medicine in 2001 to present. Dr. Higgins is affiliated with Memorial Hospital Miramar, Memorial Hospital Pembroke, Memorial Hospital West and Memorial Regional Hospital.

Dr. Higgins has a great core for alternative medicine. He always encourages his patients to seek lifestyle changes in diet, exercise, meditation and mental wellness, just to name a few.

“We are very excited to have so much new talent joining our Advisory Boards,” said President, Director, and COO Nickolas Tabraue, “We are well on our way to developing top-notch treatments to some of the most common health problems people face, and bringing on such esteemed talent to advise us will only get us there quicker.”

About Earth Science Tech:  ( www.earthsciencetech.com ) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, and Phytoceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-basedNutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore salable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (Cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products.

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com

About Earth Science Pharmaceutical:  Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry. The company is currently working on finishing the launch of its new corporate website at www.Earthsciencepharmaceutical.com

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Earth Science Tech, Inc. (305)-615-2118 Nickolas S. Tabraue, P/D/COO